MCID: MNT002
MIFTS: 60

Mental Depression

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression 12 15 72
Depressive Disorder 72
Depression 44

Classifications:



External Ids:

Disease Ontology 12 DOID:1596
MeSH 44 D003863
NCIt 50 C2982
SNOMED-CT 68 41006004
ICD10 33 F32.9 F33.9
UMLS 72 C0011570 C0011581

Summaries for Mental Depression

MalaCards based summary : Mental Depression, also known as depressive disorder, is related to atypical depressive disorder and postpartum depression, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Neuroscience and Circadian rythm related genes. The drugs Valsartan and Drospirenone have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are no effect and behavior/neurological

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2204)
# Related Disease Score Top Affiliating Genes
1 atypical depressive disorder 34.7 SLC6A4 MAOA HTR2A CRH
2 postpartum depression 34.2 SLC6A4 OXT MAOA CRH COMT BDNF
3 bipolar disorder 33.8 TPH1 SLC6A4 HTR2A HTR1A COMT BDNF
4 dysthymic disorder 33.5 SLC6A4 MAOA HTR2A
5 schizoaffective disorder 33.2 SLC6A4 HTR2A COMT BDNF
6 fibromyalgia 32.7 SLC6A4 IL6 HTR2A CRH COMT
7 bulimia nervosa 32.7 SLC6A4 HTR2A COMT BDNF
8 acth-secreting pituitary adenoma 32.5 POMC NR3C1 CRH
9 kleine-levin hibernation syndrome 32.4 TPH1 POMC COMT
10 eating disorder 32.4 SLC6A4 POMC HTR2C CRH COMT BDNF
11 autism spectrum disorder 32.3 TPH2 SLC6A4 OXT HTR2A BDNF
12 bipolar i disorder 32.3 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
13 parkinson disease, late-onset 32.2 SLC6A4 MAOA HTR2A HTR1A CYP2D6 COMT
14 migraine with or without aura 1 32.2 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1A
15 avoidant personality disorder 32.1 TPH1 SLC6A4 MAOA
16 social phobia 32.0 SLC6A4 MAOA HTR1A
17 sexual disorder 32.0 SLC6A4 OXT HTR1A
18 alexithymia 31.8 SLC6A4 HTR1A COMT
19 traumatic brain injury 31.8 IL6 COMT BDNF
20 endogenous depression 31.8 TPH1 SLC6A4 NR3C1 MAOA HTR2A HTR1A
21 brain injury 31.8 IL6 COMT BDNF
22 agoraphobia 31.7 SLC6A4 SLC6A2 MAOA HTR1A
23 substance abuse 31.6 SLC6A4 MAOA CYP2D6 COMT BDNF
24 depression 31.6 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
25 conduct disorder 31.5 TPH1 SLC6A4 MAOA COMT
26 major depressive disorder 31.3 TPH2 TPH1 SLC6A4 SLC6A2 POMC OXT
27 drug dependence 31.3 SLC6A4 POMC CRH BDNF
28 tobacco addiction 31.2 TPH1 SLC6A4 MAOA HTR2A COMT
29 antisocial personality disorder 31.2 SLC6A4 MAOA COMT
30 phobia, specific 31.2 MAOA COMT
31 autism 31.2 SLC6A4 OXT HTR2A HTR1A BDNF
32 pathological gambling 31.2 SLC6A4 MAOA HTR2A
33 tardive dyskinesia 31.2 HTR2A CYP2D6 COMT
34 personality disorder 31.2 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1A
35 borderline personality disorder 31.1 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
36 generalized anxiety disorder 31.1 TPH1 SLC6A4 SLC6A2 MAOA HTR2A HTR1A
37 schizophrenia 31.1 TPH2 TPH1 SLC6A4 SLC6A2 MAOA HTR2C
38 opiate dependence 31.1 TPH1 SLC6A4 POMC
39 premature ejaculation 31.1 SLC6A4 HTR2C HTR1A
40 oppositional defiant disorder 31.0 TPH2 SLC6A4 SLC6A2 MAOA COMT
41 phobic disorder 30.9 SLC6A4 MAOA HTR1A COMT
42 schizoid personality disorder 30.9 HTR2A HTR1A
43 post-traumatic stress disorder 30.8 SLC6A4 NR3C1 MAOA HTR2A FKBP5 CRH
44 panic disorder 30.8 TPH2 SLC6A4 SLC6A2 POMC MAOA HTR2A
45 hypoactive sexual desire disorder 30.8 HTR2A HTR1A
46 anxiety 30.8 TPH2 TPH1 SLC6A4 OXT NR3C1 MAOA
47 retrograde amnesia 30.7 SLC6A4 POMC
48 kleptomania 30.7 SLC6A4 MAOA HTR1A
49 irritable bowel syndrome 30.7 TPH1 SLC6A4 CRH
50 pervasive developmental disorder 30.6 SLC6A4 OXT BDNF

Graphical network of the top 20 diseases related to Mental Depression:



Diseases related to Mental Depression

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:


dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

GenomeRNAi Phenotypes related to Mental Depression according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 BDNF COMT CRH CYP2D6 DCTN1 DPP4

MGI Mouse Phenotypes related to Mental Depression:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 BDNF COMT CRH DCTN1 FKBP5 HTR1A
2 homeostasis/metabolism MP:0005376 10.33 BDNF COMT CRH DCTN1 DPP4 FKBP5
3 growth/size/body region MP:0005378 10.25 BDNF CRH DPP4 HTR2C IL6 NR3C1
4 cardiovascular system MP:0005385 10.22 COMT HTR1A IL6 MAOA NR3C1 OXT
5 endocrine/exocrine gland MP:0005379 10.16 BDNF COMT CRH DPP4 HTR2A IL6
6 mortality/aging MP:0010768 10.13 BDNF DCTN1 FKBP5 HTR1A HTR2C IL6
7 adipose tissue MP:0005375 10.11 CRH HTR2C IL6 NR3C1 OXT POMC
8 integument MP:0010771 10.11 BDNF CRH HTR2C IL6 NR3C1 OXT
9 nervous system MP:0003631 10.03 BDNF COMT CRH DCTN1 HTR1A HTR2C
10 muscle MP:0005369 9.86 DCTN1 HTR2A HTR2C IL6 NR3C1 SLC6A4
11 renal/urinary system MP:0005367 9.5 COMT CRH FKBP5 IL6 NR3C1 OXT
12 respiratory system MP:0005388 9.17 BDNF COMT CRH IL6 NR3C1 TPH1

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1013)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
2
Drospirenone Approved Phase 4 67392-87-4 68873
3
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
4
Carbidopa Approved Phase 4 28860-95-9 34359
5
Prucalopride Approved Phase 4 179474-81-8
6
Norethindrone Approved Phase 4 68-22-4 6230
7
Copper Approved, Investigational Phase 4 7440-50-8 27099
8
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
9
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
10
Methimazole Approved Phase 4 60-56-0 1349907
11
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
12
Trimebutine Approved Phase 4 39133-31-8
13
Lactulose Approved Phase 4 4618-18-2 11333
14
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
15
Parecoxib Approved Phase 4 198470-84-7
16
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
17
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
18
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
19
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
20
Histamine Approved, Investigational Phase 4 51-45-6 774
21
Desipramine Approved, Investigational Phase 4 50-47-5 2995
22
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
23
Zinc Approved, Investigational Phase 4 7440-66-6 32051
24
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
25
Propranolol Approved, Investigational Phase 4 525-66-6 4946
26
Memantine Approved, Investigational Phase 4 19982-08-2 4054
27
Simvastatin Approved Phase 4 79902-63-9 54454
28
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
29
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 5095 497540
30
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
31
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
32
Iloperidone Approved Phase 4 133454-47-4 71360
33
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
34
Codeine Approved, Illicit Phase 4 76-57-3 5284371
35
Trimipramine Approved Phase 4 739-71-9 5584 4055
36
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
37
Protriptyline Approved Phase 4 438-60-8 4976
38
Isocarboxazid Approved Phase 4 59-63-2 3759
39
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
40
Zolpidem Approved Phase 4 82626-48-0 5732
41
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
42
Calcium carbonate Approved, Investigational Phase 4 471-34-1
43
Terazosin Approved Phase 4 63590-64-7 5401
44
Ranibizumab Approved Phase 4 347396-82-1 459903
45
Pravastatin Approved Phase 4 81093-37-0 54687
46
Doxylamine Approved, Vet_approved Phase 4 562-10-7, 469-21-6 3162
47
Dezocine Approved, Investigational Phase 4 53648-55-8 3033053 40841
48
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
49
Rasagiline Approved Phase 4 136236-51-6 3052776
50
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
2 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
3 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
4 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
5 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
6 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
7 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
8 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
9 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
10 Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
11 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
12 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
13 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
14 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
15 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
16 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
17 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
18 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
19 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
20 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
21 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
22 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
23 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
24 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
25 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
26 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
27 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
28 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
29 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
30 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
31 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
32 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
33 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
34 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
35 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
36 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
37 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
38 Treatment Prediction in Adolescent and Adult Depression Unknown status NCT00106197 Phase 4 Bupropion
39 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
40 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
41 TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
42 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
43 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
44 Collaborative Care for Depressed Elders in China Unknown status NCT01287494 Phase 4 Sertraline
45 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
46 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
47 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
48 Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial Unknown status NCT00927550 Phase 4 lithium;usual care
49 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
50 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Genetic Tests for Mental Depression

Anatomical Context for Mental Depression

MalaCards organs/tissues related to Mental Depression:

41
Brain, Heart, Testes, Breast, Cortex, Lung, Prefrontal Cortex

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 25914)
# Title Authors PMID Year
1
Leptin gene polymorphisms are associated with weight gain during lithium augmentation in patients with major depression. 38
30554862 2019
2
Anhedonic-like behavior correlates with IFNγ serum levels in a two-hit model of depression. 38
31284015 2019
3
Reduced avoidance coping in male, but not in female rats, after mild traumatic brain injury: Implications for depression. 38
31278968 2019
4
Social rhythm regularity moderates the relationship between sleep disruption and depressive symptoms in veterans with post-traumatic stress disorder and major depressive disorder. 38
31368369 2019
5
General or specific? The memory-experience gap for individuals diagnosed with a major depressive disorder or a social phobia diagnosis, and individuals without such diagnoses. 38
31311430 2019
6
Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression. 38
31288060 2019
7
Serum miR-221-3p as a new potential biomarker for depressed mood in perioperative patients. 38
31211948 2019
8
Advanced melatonin onset relative to sleep in women with unmedicated major depressive disorder. 38
31368377 2019
9
Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors. 38
31220554 2019
10
Psychomotor retardation in depression: A critical measure of the forced swim test. 38
31255672 2019
11
Affective biases and their interaction with other reward-related deficits in rodent models of psychiatric disorders. 38
31276704 2019
12
Ketamine applications beyond anesthesia - A literature review. 38
31348905 2019
13
Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. 38
31327506 2019
14
Differential effect on myelination through abolition of activity-dependent synaptic vesicle release or reduction of overall electrical activity of selected cortical projections in the mouse. 38
30901089 2019
15
Overview of systematic reviews with meta-analyses on acupuncture in post-stroke cognitive impairment and depression management. 38
31304087 2019
16
Long-term efficacy of Metacognitive Training for Depression (D-MCT): A randomized controlled trial. 38
30556583 2019
17
Self-reported affective biases, but not all affective performance biases, are present in depression remission. 38
30854675 2019
18
Psychiatric Comorbidity and Demographic Characteristics of 1,000 Children and Adolescents With ADHD in Turkey. 38
27581245 2019
19
Cognitive Impairments in First-Episode Drug-Naïve Versus Medicated Depressive Patients: RBANS in a Chinese Population. 38
31079346 2019
20
Quantitative monitoring of a panel of stress-induced biomarkers in human plasma by liquid chromatography-tandem mass spectrometry: an application in a comparative study between depressive patients and healthy subjects. 38
31201457 2019
21
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. 38
31216565 2019
22
Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder. 38
31238203 2019
23
Chronic mild stress leads to aberrant glucose energy metabolism in depressed Macaca fascicularis models. 38
31108306 2019
24
Depressive disorders, anxiety disorders and subjective mental health in common musculoskeletal diseases: A review. 38
31351516 2019
25
Cortical thickening in remitters compared to non-remitters with major depressive disorder following 8-week antidepressant treatment. 38
31250445 2019
26
Neuroendocrine abnormalities associated with untreated first episode patients with major depressive disorder and bipolar disorder. 38
31125758 2019
27
Electroconvulsive Therapy Induces Cortical Morphological Alterations in Major Depressive Disorder Revealed with Surface-Based Morphometry Analysis. 38
31387489 2019
28
Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder. 38
31179620 2019
29
Quantifying between-cohort and between-sex genetic heterogeneity in major depressive disorder. 38
30708398 2019
30
Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive Disorder. 38
30973483 2019
31
Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions. 38
31145145 2019
32
Molecular programs underlying differences in the expression of mood disorders in males and females. 38
31129154 2019
33
Prevalence and clinical and psychological correlates of high fear of cancer recurrence in patients newly diagnosed with head and neck cancer. 38
31173429 2019
34
Neural network-based alterations during repetitive heat pain stimulation in major depression. 38
31320209 2019
35
Mental health disorder, pain, and pain treatment among long-term care residents: Evidence from the Minimum Data Set 3.0. 38
30404536 2019
36
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. 38
31255396 2019
37
Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. 38
30878146 2019
38
The ERK Pathway: Molecular Mechanisms and Treatment of Depression. 38
30737641 2019
39
Integrating digital phenotyping in clinical characterization of individuals with mood disorders. 38
31330197 2019
40
Improvement after two sessions of electroconvulsive therapy predicts final remission in in-patients with major depression. 38
31104321 2019
41
Unmet Needs of People with Serious Mental Illness: Perspectives from Certified Peer Specialists. 38
31154551 2019
42
Dementia and Cognitive Impairment Among U.S. Veterans With a History of MDD or PTSD: A Retrospective Cohort Study Based on Sex and Race. 38
29900802 2019
43
The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials. 38
31078670 2019
44
Is rTMS effective for anxiety symptoms in major depressive disorder? An efficacy analysis comparing left-sided high-frequency, right-sided low-frequency, and sequential bilateral rTMS protocols. 38
30958907 2019
45
Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. 38
31370711 2019
46
The Impact of Placebo Response Rates on Clinical Trial Outcome: A Systematic Review and Meta-Analysis of Antidepressants in Children and Adolescents with Major Depressive Disorder. 38
31368787 2019
47
Differences in the cluster of depressive symptoms between subjects with type 2 diabetes and individuals with a major depressive disorder and without diabetes. 38
30788770 2019
48
Psychotic versus non-psychotic bipolar disorder: Socio-demographic and clinical profiles in an Italian nationwide study. 38
30658550 2019
49
What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study. 38
31391190 2019
50
Validation of the Korean Version of the Depression in Old Age Scale and Comparison with Other Depression Screening Questionnaires Used in Elderly Patients in Medical Settings. 38
31352703 2019

Variations for Mental Depression

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Pathways for Mental Depression

Pathways related to Mental Depression according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 12.33 TPH2 TPH1 POMC HTR1A DCTN1 COMT
3 11.82 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
4 11.82 TPH2 TPH1 SLC6A4 NR3C1 MAOA IL6
5 11.76 POMC MAOA IL6
6
Show member pathways
11.75 HTR2C HTR2A HTR1A
7 11.62 POMC NR3C1 IL6 FKBP5
8
Show member pathways
11.19 TPH2 SLC6A4 SLC6A2 MAOA
9
Show member pathways
11.05 SLC6A4 MAOA COMT
10
Show member pathways
10.95 TPH1 MAOA COMT
11
Show member pathways
10.69 MAOA COMT
12 10.64 MAOA COMT
13 10.61 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
14 10.32 POMC CRH

GO Terms for Mental Depression

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.35 HTR2C HTR2A HTR1A COMT BDNF
2 neuron projection GO:0043005 9.02 TPH2 TPH1 SLC6A4 SLC6A2 DCTN1

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.83 SLC6A2 HTR2C HTR2A HTR1A CRH
2 female pregnancy GO:0007565 9.82 OXT CRH COMT
3 circadian rhythm GO:0007623 9.8 TPH2 TPH1 SLC6A4
4 response to glucocorticoid GO:0051384 9.76 TPH2 OXT IL6
5 response to estrogen GO:0043627 9.75 TPH2 CRH COMT
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.73 HTR2C HTR2A HTR1A
7 positive regulation of fat cell differentiation GO:0045600 9.72 TPH1 HTR2C HTR2A
8 vasoconstriction GO:0042310 9.65 SLC6A4 HTR1A
9 neuron cellular homeostasis GO:0070050 9.63 SLC6A2 DCTN1
10 locomotory exploration behavior GO:0035641 9.63 DPP4 CRH
11 behavioral fear response GO:0001662 9.63 HTR2C HTR1A DPP4
12 response to drug GO:0042493 9.63 SLC6A4 SLC6A2 HTR2C HTR2A CRH COMT
13 sleep GO:0030431 9.62 OXT HTR2A
14 neurotransmitter catabolic process GO:0042135 9.61 MAOA COMT
15 catecholamine metabolic process GO:0006584 9.61 MAOA COMT
16 monoamine transport GO:0015844 9.6 SLC6A4 SLC6A2
17 aromatic amino acid family metabolic process GO:0009072 9.59 TPH2 TPH1
18 dopamine catabolic process GO:0042420 9.57 MAOA COMT
19 memory GO:0007613 9.56 SLC6A4 OXT HTR2A BDNF
20 sperm ejaculation GO:0042713 9.54 SLC6A4 OXT
21 regulation of appetite GO:0032098 9.52 POMC HTR2C
22 response to ether GO:0045472 9.51 OXT CRH
23 response to pain GO:0048265 9.5 SLC6A2 CRH COMT
24 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.49 HTR2C HTR2A
25 serotonin biosynthetic process GO:0042427 9.48 TPH2 TPH1
26 regulation of serotonin secretion GO:0014062 9.4 HTR1A CRH
27 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.37 HTR2C HTR2A
28 serotonin receptor signaling pathway GO:0007210 9.13 HTR2C HTR2A HTR1A
29 behavior GO:0007610 8.8 HTR2C HTR2A HTR1A
30 positive regulation of cell proliferation GO:0008284 10.04 IL6 HTR2A HTR1A DPP4 CRH

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.65 POMC OXT CRH
2 drug binding GO:0008144 9.61 HTR2C HTR2A CYP2D6
3 neurotransmitter receptor activity GO:0030594 9.5 HTR2C HTR2A HTR1A
4 neurotransmitter:sodium symporter activity GO:0005328 9.46 SLC6A4 SLC6A2
5 G protein-coupled serotonin receptor activity GO:0004993 9.43 HTR2C HTR2A HTR1A
6 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A4 SLC6A2
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH2 TPH1
8 tryptophan 5-monooxygenase activity GO:0004510 9.16 TPH2 TPH1
9 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.96 HTR2C HTR2A
10 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR2A HTR1A

Sources for Mental Depression

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....